Summary: Aurora Therapeutics Deprioritizes Its PKU Gene-Editing Program

Summary: According to the Agios announcement, the company has dosed the first participant in its Phase 1b clinical trial of AG-181 in adults with PKU.

Summary: New funding will support the expansion of the existing pediatric CanPKU+ and INFORM RARE PKU Registry to include adults aged 18 and older, helping build a fuller understanding of PKU across the lifespan.